CountryOfPapers CountryOfPapers
Journal list Promote
verified COP 12,8 · D1 • database Scopus / SJR & Web of Science indexed
Cellular and Molecular Immunology
United Kingdom · Springer Nature
workspace_premium D1 Top 10% — Infectious Diseases lock Subscription

Cellular and Molecular Immunology

Cellular and Molecular Immunology is a journal indexed in SJR in Medicine (miscellaneous) and Infectious Diseases with an H index of 135. It has a COP Index of 12,8 (best band D1). It has a COP Index of 12,8.

Cellular and Molecular Immunology focuses its scope in these topics and keywords: t, immune, cells, tlr, signaling, production, inhibiting, pathway, cell, erythematosusthe, ...

ISSN: 1672-7681
Publisher: Springer Nature
Category: Medicine (miscellaneous)
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
COP Index trending_up
12,8 D1 Top 10%

5 of 277 journals in Infectious Diseases

H-index · SJR 135 · 5,916
Acceptance rate pie_chart
25% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
NPD Subscription
Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

COP Index

12,8

D1 Top 10%

SJR Impact

5,916

H-index

135

Docs (year)

131

Docs 3y

620

Total refs

9991

Cites 3y

8416

Citable 3y

412

Cites/Doc 2y

12.17

Ref/Doc

76.27

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

FAQs